ATHE Alterity Therapeutics Limited

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 2025

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Change of Director’s Interest Notice x 4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Geoffrey P. Kempler
		Geoffrey P. Kempler
		Chairman

 

Date: January 6, 2025

 

 

2

 

Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.. Amended 01/01/11

 

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ABN:	37 080 699 065

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:	Mr. Brian Meltzer
Date of Last Notice:	20 September 2024

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	30 December 2024
No. of securities held prior to change			Shares	Options
		Direct	7,142,857	9,380,952
		Indirect	326,666	-
		Total	7,469,523	9,380,952
Class	Unlisted Options
Number acquired
			Shares	Options
		Direct	-	30,000,000
		Indirect	-	-
		Total	-	30,000,000
Number disposed
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

 

 

Appendix 3Y

Change of Director’s Interest Notice

  

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a
No. of securities held after change
			Shares	Options
		Direct	7,142,857	39,380,952
		Indirect	326,666	-
		Total	7,469,523	39,380,952
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Incentive options under ESOP

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

 

Part 3 - +Closed Period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

 

 

Confidential 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001. Amended 01/01/11

 

Name of Entity:	Alterity Thesrapeutics Limited (ASX:ATH)
ABN:	37 080 699 065

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:	Mr. Peter Marks
Date of Last Notice:	20 September 2024

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	30 December 2024
No. of securities held prior to change
			Shares	Options
		Direct	-	7,000,000
		Indirect	7,185,968	2,380,952
		Total	7,185,968	9,380,952
Class	Unlisted Options
Number acquired
			Shares	Options
		Direct	-	30,000,000
		Indirect	-	-
		Total	-	30,000,000
Number disposed
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a

 

 

Confidential

 

Appendix 3Y

Change of Director’s Interest Notice

 

No. of securities held after change
			Shares	Options
		Direct	-	37,000,000
		Indirect	7,185,968	2,380,952
		Total	7,185,968	39,380,952
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Incentive options under ESOP

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

 

Part 3 - +Closed Period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

 

 

Confidential

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001. Amended 01/01/11

 

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ABM:	37 080 699 065

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:	Mr. Lawrence Gozlan
Date of Last Notice:	15 December 2022

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	30 December 2024
No. of securities held prior to change
			Shares	Options
		Direct	-	7,000,000
		Indirect	-	-
		Total	-	7,000,000
Class	Unlisted Options
Number acquired
			Shares	Options
		Direct	-	50,000,000
		Indirect	-	-
		Total	-	50,000,000
Number disposed
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

 

 

Confidential

 

Appendix 3Y

Change of Director’s Interest Notice

 

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a
No. of securities held after change
			Shares	Options
		Direct	-	57,000,000
		Indirect	-	-
		Total	-	57,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Incentive options under ESOP

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

 

Part 3 - +Closed Period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.. Amended 01/01/11

 

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ABN:	37 080 699 065

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:	Mr. Geoffrey Kempler
Date of Last Notice:	15 December 2022

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity
Date of change	30 December 2024
No. of securities held prior to change
			Shares	Options
		Direct	30,000	14,000,000
		Indirect	17,981,000	-
		Total	18,011,000	14,000,000
Class	Unlisted Options
Number acquired
			Shares	Options
		Direct	-	60,000,000
		Indirect	-	-
		Total	-	-
Number disposed
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

No. of securities held after change
			Shares	Options
		Direct	30,000	74,000,000
		Indirect	17,981,000	-
		Total	18,011,000	74,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Incentive options under ESOP

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

 

Part 3 - +Closed Period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

 

 

---